Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial

This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn). A discontinuous regimen of MR309 (400 mg/day, 5 days per cycle) was tested in patients with colorectal cancer rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruna, Jordi, Videla, Sebastián, Argyriou, Andreas A., Velasco, Roser, Villoria, Jesús, Santos, Cristina, Nadal, Cristina, Cavaletti, Guido, Alberti, Paola, Briani, Chiara, Kalofonos, Haralabos P., Cortinovis, Diego, Sust, Mariano, Vaqué, Anna, Klein, Thomas, Plata-Salamán, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794691/
https://www.ncbi.nlm.nih.gov/pubmed/28924870
http://dx.doi.org/10.1007/s13311-017-0572-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794691/
https://www.ncbi.nlm.nih.gov/pubmed/28924870
http://dx.doi.org/10.1007/s13311-017-0572-5

Ejemplares similares